Loss of proteostasis
Your cells run a constant quality-control operation on their own proteins, folding them correctly and shredding the ones that come out wrong, and this machinery is thought to weaken with age. It is one of the most elegant stories in aging biology and one of the least actionable: the evidence that it drives normal human aging is thinner than the textbook diagrams suggest, boosting it lengthens life in worms and flies but not convincingly in mammals, and outside specific diseases there is no proven way to improve it.
There is nothing proteostasis-specific worth doing: skip supplements, heat protocols and amyloid blood tests sold to healthy people on this basis. Exercise, sleep and staying metabolically healthy remain the best bets, for the reasons that have outcome data behind them rather than for anything shown about protein quality control.
What the machinery does
Loss of proteostasis is the fourth of the twelve hallmarks of aging. "Proteostasis" is short for protein homeostasis: keeping the cell's roughly ten thousand different proteins correctly folded, in the right place, and disposed of when they wear out. A protein is a chain of amino acids that only works if it folds into a precise three-dimensional shape. A misfolded one is at best useless and at worst sticky, clumping with others into aggregates the cell cannot clear. The failure of this system is the accepted explanation for Alzheimer's disease, Parkinson's disease and the amyloidoses, diseases in which a normally soluble protein turns into deposits that build up in tissue.[1]
The cell defends its proteins on three fronts:
- Chaperones fold and refold. The best-known are the heat-shock proteins, so named because they surge when a cell is heated. Their master switch is a protein called HSF1, which sits dormant until stress switches on the whole chaperone programme.
- The proteasome shreds. Proteins too far gone to rescue are tagged with a small marker called ubiquitin and fed into the proteasome, a barrel-shaped shredder that chops them back into amino acids. It handles most of the cell's routine protein turnover.
- The unfolded-protein response sounds the alarm. When misfolded proteins pile up inside the endoplasmic reticulum, the compartment where proteins for export are made, sensors throttle new protein production and boost chaperone output.[2]
A fourth arm, autophagy, digests aggregates and worn-out cell parts wholesale. It has its own hallmark and its own page: disabled macroautophagy.
Does it fail with age? In a dish, yes; in people, unclear
The human evidence that protein quality control declines with age is thin, and mostly from cells grown in a dish. The cleanest study took skin cells from donors aged 20 to 82. Their proteasome activity fell with age, and oxidised, ubiquitin-tagged proteins piled up in exactly the cells whose shredders had slowed. But the fall was in two phases: significant up to about age 50, then no further significant change between 50 and 78.[3] It came from the research arm of a cosmetics company, and its stated conclusion is about delaying skin aging.
In senescent human cells, cells that have stopped dividing but refuse to die, the response to heat is broken at HSF1 itself. After a heat challenge they got less than a third as much activated HSF1 into the nucleus, switched on their chaperone genes less strongly than young cells did, and lost 31% of their proteasome activity, a loss that deepened to 45% during what should have been recovery. They could still sense the stress; they could no longer mount a response.[4] These were fetal lung cells aged by repeated division and heated to 44 °C, which is not a 60-year-old's physiology.
Three findings argue against a simple "it wears out" story:
- The decline is not universal. Aged rat brain keeps its normal capacity to break down ubiquitin-tagged proteins.[5] In female mice, proteasome activity moved in different directions in different tissues, and the authors concluded there is no universal decline with age.[6]
- The longest-lived keep their capacity. In that mouse study, the exceptionally old animals had the best-maintained proteasome activity.
- So do centenarians' cells. Skin cells from four healthy centenarians looked like young donors' cells on every assay tried, though four cell lines is not much to build on.[7]
Human tissue data are starting to arrive. A 2025 atlas measured proteins in 516 samples from 13 human tissues, from people whose ages spanned five decades, and reported a broad decline in protein quality control, with amyloid-type deposits building up and a turning point in tissue aging around age 50.[8] A preprint, not yet peer-reviewed, measured clumped protein directly in post-mortem brain tissue from 52 disease-free women aged 20 to 88 who were cognitively normal when they died. The clumps did not simply pile up: they changed in kind from midlife, with most of the change between middle and old age and the sharpest shift after 80. People of the same age differed widely, and the amount of proteasome and chaperone machinery in a brain explained those differences about as well as age did.[9] Both studies compare different people at different ages rather than following anyone over time, and the brain study's timing differs from the skin cells, which plateau after 50.
So the flat claim "your proteostasis is failing with age" is more than the human data support. What they support is narrower: protein quality control can fail, it demonstrably does in aged and senescent cells, and human tissue is beginning to show changes that track it.
Worms and flies live longer; mammals mostly don't
Boosting protein quality control robustly lengthens life in worms and flies. In the worm C. elegans, extra copies of a proteasome part (rpn-6) extend lifespan,[10] and so does extra hsf-1, the worm's version of HSF1.[11] But an engineered version of hsf-1 extended worm lifespan without raising chaperones at all, so even in worms the gain may not come from better folding.[12] In fruit flies, switching on a proteasome part in adult neurons alone extended lifespan robustly. The same paper switched it on everywhere in the body, and lifespan did not budge while some health measures got worse.[13] More quality control is not simply better.
In mammals the lifespan results all but stop. The most encouraging result is about thinking, not lifespan: aged mouse brain loses about 70% of its working shredder capacity in one proteasome form and half in the other, and boosting a proteasome part in neurons slowed the age-related decline in learning and memory in middle-aged and old mice, with no effect in the youngest group. A short course of an experimental proteasome-activating compound did the same in old mice but not young ones.[14] The groups were small, and it came from the same laboratory as the fly work.
Only one experiment we know of in normally aging mammals claims longer life from boosting protein quality control: a nasal spray of the chaperone Hsp70 given to middle-aged and old male mice for the rest of their lives, which raised median lifespan by about 10–16%.[15] It has never been repeated, the groups were small, and the untreated mice died young, at a median of about 19–20 months against the roughly 30 months a well-run study's controls should reach; when controls die early, a treatment can look better than it is.[16] In mice bred to develop Alzheimer's-like disease, boosting the proteasome does cut early deaths, but that is rescuing a disease, not slowing aging.[17]
Where lifespan has been measured otherwise, the results have been flat or beside the point:
- Female mice engineered to make extra amounts of a proteasome-activating protein lived no longer than normal mice, though the extra protein actually lowered the capacity it was meant to raise, so it was a weak test.[18]
- The US government's multi-site mouse drug-testing programme found that 4-phenylbutyrate, a "chemical chaperone" that helps proteins fold, did not extend life in either sex and slightly shortened it in females.[19]
- The same programme found no effect from 2BAct, a drug that switches off the cell's protein-stress alarm. Halofuginone, which switches part of that alarm on, lengthened median life in male mice by about 9% (a result not adjusted for multiple comparisons) but not in females; its testers suggest it may work by mimicking a diet low in certain amino acids, which says nothing about protein quality control.[20]
Boosting the chaperone switch also carries a caution. Deleting HSF1 protects mice from tumours driven by mutations in RAS, one of the commonest cancer-causing genes, or in p53, and human cancer cells depend on it much more than non-cancerous cells do.[21] Anything that durably turns HSF1 up in a healthy adult is turning a knob that cancers also like to see turned up.
Amyloid in the brain: common, often silent, and clearing it barely helps
The strongest-sounding argument for proteostasis is Alzheimer's, Parkinson's, Huntington's and amyotrophic lateral sclerosis (ALS), all diseases of a specific protein misfolding and clumping. If clumping destroys brains, is it destroying yours a little every year? The data resist that in two ways.
Clumped protein is common and often silent. Pooling 55 studies and nearly 3,000 people with normal thinking, Alzheimer's-type amyloid in the brain was present in about 10% of 50-year-olds and 44% of 90-year-olds.[22] The same paper infers a 20-to-30-year gap between becoming amyloid-positive and developing dementia, so some of those people are early rather than exempt; but a lag that long means clumps and disease come apart over decades.
Clearing it barely helps the patient. Pooled across phase 3 trials of the whole class, including older antibodies that failed, the anti-amyloid antibodies strip amyloid out of the brain with a very large effect, more than one full standard deviation on the standard yardstick for comparing effects. Their effect on the 18-point clinician-rated dementia scale was 0.06 standard deviations, far below what a patient or clinician would notice; even donanemab, the best performer, moved it by about 0.70 points against a 1-point bar for a noticeable difference. Brain swelling became almost eight times more likely.[23] A 2026 Cochrane review of 17 trials and more than 20,000 people with mild cognitive impairment or mild dementia put that in absolute terms, about 107 more people per 1,000 showing swelling on scans across the 11 trials that reported it, called the effect on thinking trivial, and concluded that removing amyloid "does not seem to be associated with clinically meaningful effects".[24] The hope that treating longer lets a small effect grow is contested and not yet shown.
The target moved enormously and the patient barely moved. That is the cleanest test of "remove the misfolded protein, restore the function", and it came back sort of, barely.
The one success: one protein, one disease
There is a real success, and it is instructive because it is so narrow. In transthyretin amyloidosis, a blood protein called transthyretin misfolds and deposits in heart muscle, stiffening it. Tafamidis clamps the protein into its correct shape. In 441 patients over 30 months it cut deaths from any cause from 42.9% to 29.5%, about 13 fewer deaths per 100 patients treated.[25] Vutrisiran, which stops the body making the protein, cut deaths over 42 months by about 35%.[26] A second stabiliser, acoramidis, won on a combined ranking of death, hospital admission and function, though not on deaths alone.[27] The largest trial, of a second silencer called eplontersen, missed its main goal.[28] All were funded by the companies selling the drugs.
These drugs work because there is one culprit protein, with a known mechanism, causing a specific disease, in patients selected because they have it. None of that holds for ordinary aging, where the suspected problem is a diffuse loss of folding capacity with no single protein to fix. Even the silencer needs a named protein to remove. The drug class shows that protein quality control is a real target in a defined disease; it says nothing about whether a healthy 50-year-old should try to boost their chaperones.
What you can actually do: very little
Sauna for your chaperones is an inference, not a finding. The logic runs: heat raises heat-shock proteins, which are chaperones, so sauna should improve protein quality control. In people, the blood marker usually cited rose on average after a heat chamber session, but the variation between people exceeded the average effect, and blood levels say nothing about chaperones working inside cells.[29] Muscle samples after local heating disagree, and a 2025 meta-analysis found no significant change after single or repeated heat sessions, on few studies.[30] Use the sauna for the reasons that have outcome data, not to tune your proteostasis.
The supplements aimed at this have missed. Spermidine got a proper trial: 100 older adults with subjective cognitive decline, 12 months, against placebo. It improved neither memory nor the biomarkers, though the dose was 0.9 mg a day and the authors call for trials at higher doses.[31] Urolithin A, which really targets the recycling of mitochondria rather than protein folding, failed both primary goals in 66 older adults, and an early muscle-endurance benefit had gone by 4 months, in a trial run with the manufacturer's involvement.[32] Newer small trials of both have moved immune markers but not clinical outcomes.
A drug built to boost chaperones failed too. Arimoclomol turns up the heat-shock response. It did not slow decline in inclusion body myositis, a muscle disease marked by clumped protein, or in early ALS, and in both trials more people quit because of side effects (18% vs 5% and 16% vs 5%), and the ALS trial's authors say a higher dose would not have been tolerated.[33][34] If boosting chaperones does not help in diseases defined by misfolded protein, there is little reason to expect it to help a healthy person.
The general habits are the best bet, on other grounds. For exercise there is one small direct hint: older adults' muscle carried about 35% more of the stress chaperone HSP70 than untrained young adults' muscle, and 12 weeks of strength training brought it down by roughly 30%, suggesting less cellular stress.[35] That is a marker, not proof that proteins are handled better. The deep-sleep brain-clearance story is often invoked here too, but for sleep and metabolism the link to protein quality control is inference. See dementia prevention for what is known about protecting the aging brain, and genomic instability for the same empty-shelf argument in another hallmark.
You can't measure it
There is no validated blood test of "proteostasis capacity", so be wary of anyone who offers one. The aggregation-related blood tests that do work are diagnostic tools for people who already have symptoms. The 2025 Alzheimer's Association guideline covers the best of them, p-tau217, p-tau181 (fragments of the tau protein that tangles inside neurons) and the amyloid-beta 42/40 ratio, only for people with objective cognitive impairment in specialist care, and states that it "does not extend to cognitively unimpaired individuals, given the current lack of clinical relevance." It also warns that many commercially available versions do not meet its accuracy thresholds.[36] Two other markers often measured alongside them, neurofilament light and glial fibrillary acidic protein, were left out of the guideline altogether. If you are well and someone offers to measure your amyloid biology, the profession's own guideline gives no reason to.
Further reading
- Hipp MS, Kasturi P, Hartl FU. The proteostasis network and its decline in ageing. Nat Rev Mol Cell Biol 2019.[37]
- Hwang JS, et al. Age-associated decrease in proteasome content and activities in human dermal fibroblasts: restoration of normal level of proteasome subunits reduces aging markers in fibroblasts from elderly persons. J Gerontol A Biol Sci Med Sci 2007.[38]
- Ding Y, et al. Comprehensive human proteome profiles across a 50-year lifespan reveal aging trajectories and signatures. Cell 2025.[39]
- Anderton E, et al. Shifts in protein aggregate stability define proteostasis decline in the aging human brain. bioRxiv 2026 — preprint, not peer-reviewed.[40]
- Munkácsy E, et al. Neuronal-specific proteasome augmentation via Prosβ5 overexpression extends lifespan and reduces age-related cognitive decline. Aging Cell 2019 — fly study.[41]
- Parker D, et al. Proteasome augmentation mitigates age-related cognitive decline in mice. Aging Cell 2025 — mouse study.[42]
- Bobkova NV, et al. Exogenous Hsp70 delays senescence and improves cognitive function in aging mice. Proc Natl Acad Sci U S A 2015 — mouse study, unreplicated.[43]
- Harrison DE, et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used. Geroscience 2024 — NIA Interventions Testing Program.[44]
- Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015.[45]
- Avgerinos KI, et al. Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness. Sci Rep 2024.[46]
- Nonino F, et al. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2026.[47]
- Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018 — ATTR-ACT trial.[48]
- Schwarz C, et al. Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: a randomized clinical trial. JAMA Netw Open 2022 — SmartAge trial.[49]
- Palmqvist S, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement 2025.[50]